Salus (XLJU:SALR) ROCE %: 26.43% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XLJU:SALR Salus XLJU:SALR
75 GF Score
Price €67.00
GF Value €32.73
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Salus ROCE %?

Salus XLJU:SALR -1.47% 75 ROCE % is 26.43% as of Mar. 2026. GuruFocus rates XLJU:SALR with a GF Score™ of 75/100 and a GF Value™ of €32.73 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Salus's annualized ROCE % for the quarter that ended in Mar. 2026 was 26.43%.

Salus  (XLJU:SALR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Salus ROCE % Related Terms

Salus ROCE % Historical Data

* Premium members only.

The historical data trend for Salus's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Salus ROCE % Chart

Salus Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.33 20.09 14.77 17.51 20.71

Salus Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.80 21.80 19.28 23.40 26.43
XLJU:SALR
75GF Score
Salus XLJU:SALR
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Salus ROCE % Calculation

Salus's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=22.452/( ( (217.078 - 115.45) + (253.618 - 138.383) )/ 2 )
=22.452/( (101.628+115.235)/ 2 )
=22.452/108.4315
=20.71 %

Salus's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=30.46/( ( (253.618 - 138.383) + (283.75 - 168.468) )/ 2 )
=30.46/( ( 115.235 + 115.282 )/ 2 )
=30.46/115.2585
=26.43 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 26.43% mean?
Salus (XLJU:SALR) has a ROCE % of 26.43% as of Mar. 2026.
Is Salus' ROCE % too high?
Salus' current ROCE % is 26.43%. The Medical Distribution industry median ROCE % is 9.04. Salus' value of 26.43% is 192.4% above this industry median. Overall, Salus has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Salus' ROCE % compare to MCK and COR?
Salus' ROCE % of 26.43% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 9.04. Salus' value of 26.43% is 192.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 9.04, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Salus's current ROCE % of 26.43% is 192.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 9.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Salus's current ROCE % is 26.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Salus stock overvalued right now?
Based on GuruFocus' analysis, Salus (XLJU:SALR) is currently considered Significantly Overvalued. The stock's GF Value™ is €32.73, compared to a current price of €67.00 — trading 104.7% above its estimated fair value. The current ROCE % is 26.43% and 192.4% above the Medical Distribution industry median of 9.04. Salus' overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Salus (XLJU:SALR), the current ROCE % is 26.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Salus (XLJU:SALR) Overvalued in 2026?

Based on GuruFocus' analysis, Salus stock appears to be overvalued. The current stock price of €67.00 is trading 104.7% above its estimated GF Value™ of €32.73. GuruFocus considers Salus to be Significantly Overvalued.

Key valuation signals for XLJU:SALR:

  • ROCE %: 26.43%
  • GF Value™: €32.73 vs. price of €67.00 (104.7% above fair value)
  • GF Score™: 75/100 with 4 warning signs
  • Industry Position: 192.4% above the Medical Distribution median

No single metric tells the full story. See the XLJU:SALR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Salus Business Description

Other Exchanges E3U:Germany
Address Litostrojska cesta 46 A, Ljubljana, SVN, 1000
Salus is a Slovenia-based company engaged in the wholesale and distribution of medical products. It offers medicines, medical devices, medical supplies, dietary supplements, cosmetics to hospitals, pharmacies, and other customers.
75GF Score

Get the complete analysis for XLJU:SALR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€67.00
Price
€32.73
GF Value